Home Compare ABBV vs LLY
Stock Comparison · Industry comparison · Drug Manufacturers - General

AbbVie vs Eli Lilly and Company: Which Stock Looks Stronger in 2026?

Eli Lilly and Company holds the cleaner structural position, with profitability as the main driver and stability adding further support. AbbVie still has the edge on stability, which keeps the comparison from looking entirely one-sided. The market setup is broadly comparable for both — no clear directional signal from price behavior. The market is not adding a decisive signal either way — the structural read carries the weight.

The comparison is based on similar long-term financial trajectories, not sector labels. Both peer scores are relative to the S&P 500 universe, making them directly comparable.

Updated 2026-08-16

The comparison is mainly decided in profitability, with the rest of the profile carrying less weight. Eli Lilly and Company leads by 14 points on the overall comparison score.

INDUSTRY COMPARISON

Both operate in: Drug Manufacturers - General

This comparison is based on industry proximity, not on functional trajectory similarity. ABBV and LLY share the same industry classification.

For a similarity-based comparison, see how AbbVie and Eli Lilly and Company each position within their functional peer groups in AssetNext.

Peer-Relative Score
ABBV
AbbVie Inc.
52
Peer-Score
Signal qualityHigh
Peer basis: S&P 500
vs
LLY
Eli Lilly and Company
66
Peer-Score
Signal qualityHigh
Peer basis: S&P 500

Scores reflect position relative to comparable companies with similar long-term financial trajectories.

Score differences across key dimensions.

Dimension spread: ABBV vs LLY Profitability 43 100 Stability 68 34 Valuation 27 46 Growth 84 75 ABBV LLY
Gap Ranking
#1 Profitability +57
#2 Stability +34
#3 Valuation +19
#4 Growth +9
Price Setup

Left means cheaper relative valuation. Higher means stronger structure.

Price setup map for ABBV and LLY Stronger + cheaper Stronger + richer Weaker + cheaper Weaker + richer ABBVLLY Relative valuation Structural strength

The structural gap is limited here, but current pricing still leans against AbbVie Inc..

Valuation position uses peer-relative PE percentile (idx_pct_pe) where available.

Entry today — historical context

Where ABBV and LLY each sit in their own 5-year price and valuation history.

BASED ON 5-YEAR HISTORY ABBV Elevated · above norm 0th 50th 100th 0 pct gap LLY Elevated · below norm 0th 50th 100th 98th 98th
ABBV (98th percentile) and LLY (98th percentile) both sit in the upper portion of their own 5-year ranges. The historical entry context is broadly similar for both. This reflects entry timing, not which company is structurally stronger.

Describes historical entry positioning only. Descriptive — not investment advice.

Relative Position vs Comparable Companies
Profitability
Both rank well on profitability, but Eli Lilly and Company still holds a clear edge.
Stability
On stability, the gap still runs the same way: AbbVie Inc. sits near the top of the group, while Eli Lilly and Company remains in the weaker half.
Profitability — Dominant Gap
ABBV
43
LLY
100
Gap+57in favour of LLY

The profitability lead is mainly driven by a 14.2-point operating margin advantage.

What keeps the gap from being one-sided

Stability still leans toward AbbVie Inc., so the lead is real without reading as one-way.

What this means for the comparison

Profitability settles the comparison, while pricing and stability keep the broader setup from looking fully aligned.

Explore full peer positioning in AssetNext

Break down the ABBV vs LLY comparison across all dimensions with the full interactive tool.

Explore full breakdown →
Other comparisons with conflicting dimension signals

Explore how ABBV and LLY each compare against other companies in their peer groups.

Rule-based, descriptive analysis only. Derived from peer percentile dimensions. Not investment advice. Peer groups are determined algorithmically based on structural similarity — not by sector classification alone.

How AssetNext Peer Scores Work

AssetNext scores reflect each company's structural position within its functional peer group — not a ranking against all stocks simultaneously. Peers are identified by similarity across eight financial dimensions, including revenue growth trajectory, margin structure, capital intensity, and earnings stability. A score of 75 means the company ranks in the top quartile within its own peer group, not the entire market.

Four dimension scores drive the overall peer score: Growth (revenue trajectory and expansion dynamics), Quality (margin structure and capital efficiency), Valuation (peer-relative pricing on standard multiples), and Stability (earnings consistency and financial predictability). Each dimension is scored 0–100 relative to the peer group, then combined into an overall peer score using equal weighting.

Because scores are peer-relative, the same company can have slightly different scores in different index universes. On comparison pages, both companies are shown within their shared peer universe wherever possible — so the scores are directly comparable. The peer basis is stated on each score card.

Scores are recalculated periodically as underlying financial data is updated. All analysis is descriptive and rule-based — AssetNext describes structural realities and never issues buy, sell or hold recommendations.